Novo CEO Says Planned Semaglutide GLP-1 Pill Reflects Innovative Strategy
This article was originally published in The Pink Sheet Daily
Executive Summary
Novo Nordisk says plans to start Phase II studies of an oral version of its once-weekly injected human GLP-1 analogue semaglutide reflect the Danish company’s commitment to innovate by addressing a wider segment of the growing diabetes and pre-diabetes market.